临床试验/NCT01707745

NCT01707745Unknown不适用

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Sivakami A Pai1 个研究点分布在 1 个国家目标入组 50 人开始时间: 2010年1月最近更新: 2012年10月16日

适应症

试验速览

阶段: 不适用
发起方
入组人数: 50
试验地点: 1
主要终点: Regression Of ROP

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).

Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 32 Weeks 至 42 Weeks（Child）
性别: All
接受健康志愿者: 否

入选标准

•stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II.
•Informed written consent by parents or guardian.

排除标准

•Refusal to give consent Critically ill neonates.

结局指标

主要结局

Regression Of ROP

时间窗: Minimum 6 months follow up after intravitreal Avastin

次要结局

Recurrence of ROP(minimum 6 months of follow up.)

研究者

发起方

Sivakami A Pai

申办方类型

Other Gov

责任方

Sponsor Investigator

主要研究者

Sivakami A Pai

Doctor

Dubai Health Authority

研究点 (1)

Loading locations...

相似试验

Study for efficacy and safety of intravitreal injection of bevacizumab (Avastin)diabetic retinopathy central retinal vein occulusion, neovascular glaucoma

JPRN-UMIN000012248ational Center for Global Health and Medicine, Kohnodai Hospital20

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic RetinopathyProliferative Diabetic Retinopathy

NCT01025934University of Campania "Luigi Vanvitelli"

Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic RetinopathyProliferative Diabetic RetinopathyDiabetic Traction Retinal DetachmentVitreous Hemorrhage

NCT01854593Nihon University69

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)Diabetic Retinopathy

NCT00370721Shahid Beheshti University of Medical Sciences

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of PrematurityRetinopathy of Prematurity

NCT00622726The University of Texas Health Science Center, Houston150